Disease Domain | Count |
---|---|
Nervous System Diseases | 5 |
Endocrinology and Metabolic Disease | 3 |
Neoplasms | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 16 |
Target |
Mechanism nAChRα4&β2 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date10 May 2006 |
Target |
Mechanism Cardiac myosin inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism L-type calcium channel blockers |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Apr 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date19 Dec 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Varenicline Tartrate ( nAChRα4&β2 ) | Xerophthalmia More | Approved |
Omecamtiv Mecarbil ( Cardiac myosin ) | Heart Failure More | NDA/BLA |
Etripamil ( L-type calcium channel ) | Paroxysmal supraventricular tachycardia More | NDA/BLA |
Aficamten ( Cardiac myosin ) | Hypertrophic obstructive cardiomyopathy More | NDA/BLA |
OC-02 ( nAChRs ) | Dry Eye Syndromes More | Phase 3 |